Review



mouse anti human egf neutralizing antibody ntab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems mouse anti human egf neutralizing antibody ntab
    (A) ELISA of <t>EGF,</t> TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after <t>EGF-neutralizing</t> antibody <t>(NtAb)</t> treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.
    Mouse Anti Human Egf Neutralizing Antibody Ntab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Mouse+anti-Human+IgG1+Fc+Secondary+Antibody+(2C11)/pmc10162546-57-0-18
    Average 93 stars, based on 7 article reviews
    mouse anti human egf neutralizing antibody ntab - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners"

    Article Title: Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners

    Journal: PLOS ONE

    doi: 10.1371/journal.pone.0285354

    (A) ELISA of EGF, TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after EGF-neutralizing antibody (NtAb) treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.
    Figure Legend Snippet: (A) ELISA of EGF, TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after EGF-neutralizing antibody (NtAb) treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Incubation, Control, Concentration Assay, Recombinant, MTT Assay, Expressing, Western Blot

    Related Articles

    Positive Control:

    Article Title: Soluble Factors from Human Olfactory Neural Stem/Progenitor Cells Influence the Fate Decisions of Hippocampal Neural Precursor Cells.
    Article Snippet: Neurogenesis plays a significant role during adulthood, and the observation that neural stem cells reside in the central nervous system and the olfactory epithelium has attracted attention due to their importance in neuronal regeneration.. In addition, soluble factors (SFs) release by neural stem cells maymodulate the neurogenic process.. Thus, in this study, we identified the SFs released by olfactory human neural stem/progenitor cells (hNS/PCs-OE).

    Concentration Assay:

    Article Title: Soluble Factors from Human Olfactory Neural Stem/Progenitor Cells Influence the Fate Decisions of Hippocampal Neural Precursor Cells.
    Article Snippet: Neurogenesis plays a significant role during adulthood, and the observation that neural stem cells reside in the central nervous system and the olfactory epithelium has attracted attention due to their importance in neuronal regeneration.. In addition, soluble factors (SFs) release by neural stem cells maymodulate the neurogenic process.. Thus, in this study, we identified the SFs released by olfactory human neural stem/progenitor cells (hNS/PCs-OE).

    Incubation:

    Article Title: Soluble Factors from Human Olfactory Neural Stem/Progenitor Cells Influence the Fate Decisions of Hippocampal Neural Precursor Cells.
    Article Snippet: Neurogenesis plays a significant role during adulthood, and the observation that neural stem cells reside in the central nervous system and the olfactory epithelium has attracted attention due to their importance in neuronal regeneration.. In addition, soluble factors (SFs) release by neural stem cells maymodulate the neurogenic process.. Thus, in this study, we identified the SFs released by olfactory human neural stem/progenitor cells (hNS/PCs-OE).

    Blocking Assay:

    Article Title: Significance of salivary epidermal growth factor in peptic ulcer disease in hemodialysis patients.
    Article Snippet: Background/Aims: Hemodialysis (HD) patients are prone to developing peptic ulcers.. However, of all the risk factors associated with peptic ulcers, none have been shown to be more prevalent in HD patients than in the general population.. However, salivary epidermal growth factor (EGF) may play a role in peptic ulcer diseases.



    Similar Products

    mouse anti human egf neutralizing antibody ntab  (R&D Systems)
    93
    R&D Systems mouse anti human egf neutralizing antibody ntab
    (A) ELISA of <t>EGF,</t> TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after <t>EGF-neutralizing</t> antibody <t>(NtAb)</t> treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.
    Mouse Anti Human Egf Neutralizing Antibody Ntab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Mouse+anti-Human+IgG1+Fc+Secondary+Antibody+(2C11)/pmc10162546-57-0-18
    Average 93 stars, based on 1 article reviews
    mouse anti human egf neutralizing antibody ntab - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti epidermal growth factor egf  (R&D Systems Hematology)
    93
    R&D Systems Hematology anti epidermal growth factor egf
    (A) ELISA of <t>EGF,</t> TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after <t>EGF-neutralizing</t> antibody <t>(NtAb)</t> treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.
    Anti Epidermal Growth Factor Egf, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+EGF+Antibody/pm35482455-33-14-19
    Average 93 stars, based on 1 article reviews
    anti epidermal growth factor egf - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    egf neutralizing antibody  (R&D Systems)
    93
    R&D Systems egf neutralizing antibody
    (A) ELISA of <t>EGF,</t> TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after <t>EGF-neutralizing</t> antibody <t>(NtAb)</t> treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.
    Egf Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+EGF+Antibody/pmc09175134-42-6-10
    Average 93 stars, based on 1 article reviews
    egf neutralizing antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti hb egf neutralizing antibody  (R&D Systems)
    95
    R&D Systems anti hb egf neutralizing antibody
    TNIIIA2 secreted SASP factors, including <t>HB-EGF,</t> induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF <t>neutralizing</t> antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.
    Anti Hb Egf Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+HB-EGF+Antibody/pmc08493383-57-11-18
    Average 95 stars, based on 1 article reviews
    anti hb egf neutralizing antibody - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    persistent id url nrg1 antibody r d systems af 396 na neutralizing ab enos antibody bd biosciences  (R&D Systems)
    92
    R&D Systems persistent id url nrg1 antibody r d systems af 396 na neutralizing ab enos antibody bd biosciences
    TNIIIA2 secreted SASP factors, including <t>HB-EGF,</t> induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF <t>neutralizing</t> antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.
    Persistent Id Url Nrg1 Antibody R D Systems Af 396 Na Neutralizing Ab Enos Antibody Bd Biosciences, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+NRG1-beta+1%2FHRG1-beta+1+EGF+Domain+Antibody/pmc08288485__atv___41___2293___s001-7-15-21
    Average 92 stars, based on 1 article reviews
    persistent id url nrg1 antibody r d systems af 396 na neutralizing ab enos antibody bd biosciences - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti human egf neutralizing antibody  (R&D Systems)
    92
    R&D Systems anti human egf neutralizing antibody
    TNIIIA2 secreted SASP factors, including <t>HB-EGF,</t> induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF <t>neutralizing</t> antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.
    Anti Human Egf Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+EGF+Antibody/pm29498005-100-30-40
    Average 92 stars, based on 1 article reviews
    anti human egf neutralizing antibody - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti egf neutralizing antibody egf ab 236 na  (R&D Systems)
    93
    R&D Systems anti egf neutralizing antibody egf ab 236 na
    TNIIIA2 secreted SASP factors, including <t>HB-EGF,</t> induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF <t>neutralizing</t> antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.
    Anti Egf Neutralizing Antibody Egf Ab 236 Na, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+EGF+Antibody/pmc04767392-132-5-12
    Average 93 stars, based on 1 article reviews
    anti egf neutralizing antibody egf ab 236 na - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti egf neutralizing antibody  (R&D Systems)
    93
    R&D Systems anti egf neutralizing antibody
    TNIIIA2 secreted SASP factors, including <t>HB-EGF,</t> induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF <t>neutralizing</t> antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.
    Anti Egf Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+egf+neutralizing+antibody/Human+EGF+Antibody/pmc04767392-199-37-44
    Average 93 stars, based on 1 article reviews
    anti egf neutralizing antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) ELISA of EGF, TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after EGF-neutralizing antibody (NtAb) treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.

    Journal: PLOS ONE

    Article Title: Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners

    doi: 10.1371/journal.pone.0285354

    Figure Lengend Snippet: (A) ELISA of EGF, TNF-α, IL-6, and TGF-β1 was performed with the culture supernatants of nonadherent NL20, BEAS-2B, and 16HBE 4–6 days after incubation with autocrine CS or BPDE CM compared with the autocrine control CM. ELISA of EGF, TNF-α, and IL-6 was also conducted with the culture supernatants 48 h after exposure to CS in adherent bronchial cell lines. Asterisks indicate a significant difference in concentration (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (B) Anchorage-independent growth of NL20, BEAS-2B, and 16HBE cells was measured using MTT 5–6 days after the administration of recombinant human EGF, TNF-α, and IL-6. The MTT assay was performed for autocrine CS CM-incubated nonadherent NL20 and BEAS-2B cells four and five days after EGF-neutralizing antibody (NtAb) treatment, respectively, and for autocrine CS CM-incubated nonadherent 16HBE cells, five days after TNF-α NtAb treatment. The MTT assay was also performed for autocrine CS CM-incubated nonadherent bronchial cell lines five days after IL-6 NtAb administration. Asterisks indicate a significant difference in growth (*p < 0.05, **p < 0.01). Relative values are shown as mean ± SD from three independent experiments. (C) Expression of BRD4 and EZH2 in nonadherent 16HBE cells three days after the administration of recombinant human TNF-α determined using western blotting and the expression of BRD4 and EZH2 3–4 days after treatment of nonadherent NL20 and BEAS-2B cells with recombinant human EGF.

    Article Snippet: Mouse anti-human EGF neutralizing antibody (NtAb), goat anti-human TNF-α NtAb, and mouse anti-human IL-6 NtAb were obtained from R&D Systems.

    Techniques: Enzyme-linked Immunosorbent Assay, Incubation, Control, Concentration Assay, Recombinant, MTT Assay, Expressing, Western Blot

    TNIIIA2 secreted SASP factors, including HB-EGF, induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.

    Journal: American Journal of Cancer Research

    Article Title: Induction of cellular senescence in fibroblasts through β1-integrin activation by tenascin-C-derived peptide and its protumor effect

    doi:

    Figure Lengend Snippet: TNIIIA2 secreted SASP factors, including HB-EGF, induce the malignant transformation of HaCaT cells. In (A and B), HaCaT cells cocultured with TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control. After incubation for 72 h, the HaCaT area was measured by rhodanile blue staining. Scale bar, 200 μm. (C) HaCaT cells treated with CM from TNIIIA2-induced senescent WI-38 cells were incubated with either an anti-HB-EGF neutralizing antibody or isotype control and then subjected to a WST-8 (D) or colony formation (E) assay. (F) WI-38 cells were treated with either TNIIIA2 (50 μg/mL) or NaB (4 mM) to induce cellular senescence, as described in the Materials and Methods. HB-EGF and GAPDH mRNA levels were then measured by semi-quantitative PCR. In (G and H), HaCaT cells were treated with recombinant human HB-EGF, and the cells were subjected to a WST-8 assay on day 2 (G) or colony formation assay on day 10 (H). Data are presented as means ± SD, *P < 0.05, **P < 0.01.

    Article Snippet: Recombinant human heparin-binding epidermal growth factor-like growth factor (HB-EGF) and an anti-HB-EGF neutralizing antibody (AF-259-NA) were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Transformation Assay, Incubation, Control, Staining, Real-time Polymerase Chain Reaction, Recombinant, Colony Assay

    A model of malignant transformation of preneoplastic cells via factors secreted from TNIIIA2-induced senescent fibroblasts. Activation of β1-integrin by TNIIIA2 induces fibroblast senescence. Factors secreted by TNIIIA2-induced senescent fibroblasts, including HB-EGF, are involved in the malignant transformation of preneoplastic cells. Inactivation of β1-integrin by peptide FNIII14 inhibits TNIIIA2-induced cellular senescence. Created using BioRender.com.

    Journal: American Journal of Cancer Research

    Article Title: Induction of cellular senescence in fibroblasts through β1-integrin activation by tenascin-C-derived peptide and its protumor effect

    doi:

    Figure Lengend Snippet: A model of malignant transformation of preneoplastic cells via factors secreted from TNIIIA2-induced senescent fibroblasts. Activation of β1-integrin by TNIIIA2 induces fibroblast senescence. Factors secreted by TNIIIA2-induced senescent fibroblasts, including HB-EGF, are involved in the malignant transformation of preneoplastic cells. Inactivation of β1-integrin by peptide FNIII14 inhibits TNIIIA2-induced cellular senescence. Created using BioRender.com.

    Article Snippet: Recombinant human heparin-binding epidermal growth factor-like growth factor (HB-EGF) and an anti-HB-EGF neutralizing antibody (AF-259-NA) were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Transformation Assay, Activation Assay